Goldman Sachs
NTLA icon

Goldman Sachs’s Intellia Therapeutics NTLA Stock Holding History

Goldman Sachs’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,200
Closed -$152K – 6558
2025
Q2 		$152K Hold
16,200
– – ﹤0.01% 5734
2025
Q1 		$115K Buy
+16,200
New +$164K ﹤0.01% 5759
2022
Q1 		– Sell
-15,000
Closed -$1.77M – 6806
2021
Q4 		$1.77M Buy
+15,000
New +$1.88M ﹤0.01% 4347

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Goldman Sachs's NTLA Position: Q2 2026 in Review

Goldman Sachs increased its Intellia Therapeutics (NTLA) stake by 39% in Q2 2026, buying an estimated $8.9M and bringing the position to 2,264,471 shares worth $38.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2037.

Goldman Sachs first reported a position in NTLA in Q2 2016 and has held it in 41 quarters since. The position peaked at $161M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Goldman Sachs held 2,264,471 shares of Intellia Therapeutics worth $38.3M as of Q2 2026.
  • Goldman Sachs bought 636,230 Intellia Therapeutics shares in Q2 2026, an estimated $8.9M.
  • Intellia Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2037 holding.
  • Goldman Sachs first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 41 quarters since.
  • Goldman Sachs's Intellia Therapeutics position peaked at $161M in Q2 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.